Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00643604 · ClinicalTrials.gov registry record · Phase 4
Rapid Switch From Flolan to Remodulin in the Outpatient Clinic
A Phase 4 study, sponsored by United Therapeutics.
- Terminated
- Registry status
- Phase 4
- Development phase
- 7
- Enrollment target
NCT00643604: Clinical Trial Phase 4 study, sponsored by United Therapeutics.
NCT00643604 is a Phase 4 study that was terminated before completion, run by United Therapeutics. The registered enrollment target is 7 participants, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00643604, a Phase 4 study, was terminated before completion, sponsored by United Therapeutics.
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 7 participants
- Enrollment target
Study Summary
The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
Interventions
- DRUG treprostinil sodium
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 7 participants |
| Start Date | 2008-03 |
| Est. Completion | 2012-02 |
| Phase | Phase 4 |
Why NCT00643604 stopped before completion
NCT00643604 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 7 participants, a relatively small participant target, below the 518-participant average among 9,235 other Phase 4 trials with a reported enrollment target (99% lower).
The record links to 0 conditions, and to 1 intervention - of which treprostinil sodium is the first listed.
NCT00643604 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00643604 about?
NCT00643604 is a clinical study titled "Rapid Switch From Flolan to Remodulin in the Outpatient Clinic". The purpose of this 8-week study is to compare the effects of switching from therapy with epoprostenol or Flolan to IV Remodulin. This study will also assess the effect that changing to Remodulin will have on patient satisfaction with their treatment and impact on quality of life.
What is the current status of trial NCT00643604?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 7 participants. The study started on 2008-03. Estimated completion is 2012-02.
What interventions are being tested in trial NCT00643604?
The interventions under investigation include: treprostinil sodium (DRUG).
Who is sponsoring clinical trial NCT00643604?
This trial is sponsored by United Therapeutics, which has 63 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00643604's enrollment target sits among peer trials
7 1981st of 2000 higher than 18 of 2,000 other Phase 4 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 4 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia